Chlorophyllin has been investigated for its potential to mitigate the effects of certain chemical poisons, particularly aflatoxins, which are toxic compounds produced by molds. Scientific studies, especially those led by Dr. George S. Bailey and colleagues in the 1990s and 2000s, have shown that chlorophyllin can bind to aflatoxins in the digestive tract, reducing their bioavailability and subsequent absorption into the body. This effect was observed in animal studies and later supported by human clinical trials, notably a randomized trial in China where chlorophyllin supplementation was associated with reduced levels of aflatoxin-DNA adducts, a biomarker of exposure, in individuals at high risk for aflatoxin exposure.

The proposed mechanism is that chlorophyllin forms non-covalent complexes with certain planar aromatic compounds, limiting their uptake and facilitating excretion. While most of the evidence centers around aflatoxins, there is limited but promising data suggesting that chlorophyllin may similarly interact with other chemical carcinogens or toxins. However, evidence for its efficacy against a broader range of chemical poisons (e.g., industrial chemicals, pesticides, or heavy metals) remains insufficient, and its use in acute poisoning scenarios is not established.

Overall, the use of chlorophyllin to support detoxification from specific chemical toxins, especially aflatoxins, is supported by moderate-quality clinical and preclinical evidence, but its general application for "chemical poisoning" is not broadly validated.